BioBetter™ Making modern medicine (biological drugs) affordable for everyone

Biologic drugs produced only in living systems and offer revolutionary treatment for unmet clinical needs. 1 in 3 new drugs approved today – biologics; 40% of the biopharma R&D pipeline consists of biologics; biologics market worth $250B; $500B by 2025 (CAGR: 10%-11%).
When the exclusivity expires, biologics face competition from follow-on products called ‘biosimilars’. Their market is projected to reach $60B by 2025 (CAGR: 25%-30%).
The problem: Biologics, and biosimilars, are very expensive – average price in the US: $10 – $50K/year; some exceeding $500K/year. Therefore only a fraction of the patients can afford it. Manufacturing in traditional platforms is risky and costly, 1gr. of API costs $500 to $1,000.
Solution: BioBetter revolutionary, proprietary production platform using Tobacco plants in the open-field plantation as bioreactors. Our unique genetic engineering and purification process reduce the production costs by over 95% and enables vast affordability of biologic drugs.

Stage Startup stage EST July 2015
Sectors Agritech, Biotechnology and medical research, Pharmaceuticals
Location Qiryat Shemona, Israel
Markets Global
Customer model Governments (B2G)
Contact Login to view details
Social media